CD103 is a hallmark of tumor‐infiltrating regulatory T cells
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Regulatory T cells (Treg) mediate tolerance towards self‐antigens by suppression of innate and adaptive immunity. In cancer patients, tumor‐infiltrating FoxP3+ Treg suppress local anti‐tumor immune responses and are often associated with poor prognosis. Markers that are selectively expressed on tumor‐infiltrating Treg may serve as targets for immunotherapy of cancer. Here we show that CD103, an integrin mediating lymphocyte retention in epithelial tissues, is expressed at high levels on tumor‐infiltrating FoxP3+ Treg in several types of murine cancer. In the CT26 model of colon cancer up to 90% of the intratumoral FoxP3+ cells expressed CD103 compared to less than 20% in lymphoid organs. CD103+ Treg suppressed T effector cell activation more strongly than CD103 neg Treg. Expression of CD103 on Treg closely correlated with intratumoral levels of transforming growth factor β (TGF‐β) and could be induced in a TGF‐β‐dependent manner by tumor cell lines. In vivo, gene silencing of TGF‐β reduced the frequency of CD103+ Treg, demonstrating that CD103 expression on tumor‐infiltrating Treg is driven by intratumoral TGF‐β. Functional blockade of CD103 using a monoclonal antibody did however not reduce the number of intratumoral Treg, indicating that CD103 is not involved in homing or retention of FoxP3+ cells in the tumor tissue. In conclusion, expression of CD103 is a hallmark of Treg that infiltrate TGF‐β‐secreting tumors. CD103 thus represents an interesting target for selective depletion of tumor‐infiltrating Treg, a strategy that may help to improve anti‐cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“In particular, Treg infiltrating the tumor tissue itself inhibit anti-cancer immunity and correlate with poor prognosis in many types of human cancer.(4,5,25) A comprehensive knowledge of the phenotype of tumor-infiltrating Treg is crucial to understand their mode of action and to develop thera-”
BackgroundRational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094 · cited 1×
“For in vivo gene silencing of TGF-b, siRNAs were designed according to published guidelines.(21) 30-Overhangs were carried out as two deoxythymidine residues (dTdT).”
MethodAdhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrin
Cepek, K. L., Shaw, S. K., Parker, C. M., Russell, G. J., Morrow, J. S., Rimm, D. L., & Brenner, M. B. (1994) · Nature · doi:10.1038/372190a0 · Cited by 1,178
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.102 · Cited by 897
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Cited by
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Harjunpää, H., Llort Asens, M., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 764
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
Allen, B. M., Hiam, K. J., Burnett, C. E., Venida, A., DeBarge, R., Tenvooren, I., Marquez, D. M., Cho, N. W., Carmi, Y., & Spitzer, M. H. (2020) · Nature Medicine · doi:10.1038/s41591-020-0892-6 · Cited by 328
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
“Indeed, in the context of tumor immunity, it has been shown that tumor-infiltrating Treg expressed significantly higher levels of Integrin αE (CD103) than peripheral Tregs and that CD103+ Treg displayed a more suppressive phenotype [221].”
BackgroundTissue-resident memory T cells at the center of immunity to solid tumors
Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 278
mTOR Signaling, Tregs and Immune Modulation
Chapman, N. M., & Chi, H. (2014) · Immunotherapy · doi:10.2217/imt.14.84 · Cited by 148
Metadata
- Authors
- Anz, D., Mueller, W., Golic, M., Kunz, W. G., Rapp, M., Koelzer, V. H., Ellermeier, J., Ellwart, J. W., Schnurr, M., Bourquin, C., & Endres, S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-04
- Volume
- 129
- Issue
- 10
- Pages
- 2417-2426
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1999999047
- Cited by
- 116
- References
- 7
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.